**Table S1. Additional clinical information for patients in MSKCC cohort.**

|  |  |
| --- | --- |
| **MSKCC** **(n=189 patients)** | |
| **ECOG PS, N (%)** |  |
| 0 | 121 (64.0%) |
| 1 | 63 (33.3%) |
| 2 | 5 (2.6%) |
| **Adjuvant/neoadjuvant chemotherapy, N (%)** |  |
| Yes – platinum/taxane | 142 (75.1%) |
| Yes – other | 5 (2.6%) |
| No | 42 (22.2%) |
| **Adjuvant radiation, N (%)** |  |
| Yes – IVRT | 53 (28.0%) |
| Yes – WPRT | 25 (13.2%) |
| Yes – both IVRT and WPRT | 16 (8.5%) |
| Yes – outside radiation | 2 (1.1%) |
| No | 93 (49.2%) |
| **Hormonal therapy, N (%)** |  |
| Yes – aromatase inhibitor | 19 (10.1%) |
| Yes – single-agent megestrol acetate (Megace) | 12 (6.3%) |
| Yes – tamoxifen alternating with Megace | 6 (3.2%) |
| Yes –single-agent tamoxifen | 5 (2.6%) |
| Yes - leuprolide | 2 (1.1%) |
| Yes – fulvestrant | 2 (1.1%) |
| No | 149 (78.8%) |
| **Clinical Trial, N (%)** |  |
| Yes – matched | 44 (23.3%) |
| Yes – unmatched | 26 (13.8%) |
| No | 119 (63.0%) |
| **Metastatic Site, N (%)** |  |
| Lymph Node | 18 (18.2%) |
| Lung | 16 (16.2%) |
| Omentum | 14 (14.1%) |
| Pelvis | 11 (11.1%) |
| Abdomen | 7 (7.1%) |
| Peritoneum/Ascites | 6 (6.1%) |
| Vagina | 5 (5.1%) |
| Liver | 5 (5.1%) |
| Colon/Rectum | 5 (5.1%) |
| Bone/Soft Tissue | 4 (4.0%) |
| Chest Wall | 2 (2.0%) |
| Diaphragm | 2 (2.0%) |
| Kidney | 1 (1.0%) |
| Retroperitoneum | 1 (1.0%) |
| Spleen | 1 (1.0%) |
| Ureter | 1 (1.0%) |